INVA Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Antheia

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

6 days ago - By: Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

19 days ago - By: Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

26 days ago - By: Benzinga

Beyond The Numbers: 5 Analysts Discuss Innoviva Stock

3 months ago - By: Benzinga

Expert Outlook: Innoviva Through The Eyes Of 4 Analysts

3 months ago - By: The Motley Fool

Innoviva (INVA) Q2 Sales Jump 64%

2 months ago - By: Innoviva, Inc.

Innoviva to Participate in Upcoming Investor Conferences

2 months ago - By: Innoviva Specialty Therapeutics, Inc.

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

3 months ago - By: Yahoo Finance - Mentions: MS CMI HSBC LINE ...

Arm initiated, Adobe downgraded: Wall Street's top analyst calls

3 months ago - By: Innoviva, Inc.

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

5 months ago - By: Innoviva Specialty Therapeutics, Inc.

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

5 months ago - By: Innoviva, Inc.

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

5 months ago - By: Innoviva, Inc.

Innoviva to Participate in Upcoming Investor Conferences

5 months ago - By: Innoviva Specialty Therapeutics, Inc.

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

6 months ago - By: Yahoo Finance - Mentions: MSFT AMZN

Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling

6 months ago - By: Innoviva, Inc.

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

8 months ago - By: Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

8 months ago - By: Innoviva, Inc.

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

8 months ago - By: Innoviva, Inc.

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

9 months ago - By: Innoviva, Inc.

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

10 months ago - By: Innoviva, Inc.

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

a year ago - By: Innoviva, Inc.

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

a year ago - By: Innoviva, Inc.

INNOVIVA INC (INVA) Stock News

INVA Latest News, Press Relases and Analysis

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Beyond The Numbers: 5 Analysts Discuss Innoviva Stock

Expert Outlook: Innoviva Through The Eyes Of 4 Analysts

Innoviva (INVA) Q2 Sales Jump 64%

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Arm initiated, Adobe downgraded: Wall Street's top analyst calls

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Innoviva to Participate in Upcoming Investor Conferences

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Innoviva to Participate in the UBS Global Healthcare Conference